Unigen Signs Licensing Agreement With Basic Research

Unigen Signs Licensing Agreement With Basic Research

BROOMFIELD, Colo., & SALT LAKE CITY--UnigenPharmaceuticals and Basic Research Inc. announced they had concluded a licensingagreement for Unigen's proprietary, patent-pending dietary supplement Univestin.Under the multiple-year agreement, Salt Lake City-based Basic Research hasexclusive rights to market Univestin to the retail health food, magazine andinfomercial marketing channels. The agreement covers the United States, Canada,Mexico, Japan, Pakistan and the European Union.

"Our collaboration with Basic Research provides an avenueto build upon our success in the industry," said Regan Miles, vicepresident of sales and marketing for Broomfield, Colo.-based Unigen. "Thisagreement further expands Unigen's presence while fulfilling the demand forUnivestin."

Univestin is Unigen's proprietary botanical compound that hasbeen studied for its ability to promote increased mobility and healthy jointfunction. It is currently being used in a double blind, placebo-controlled humanclinical trial in Montreal.

For more information, visit www.unigenpharma.comor Booth #1500 at SupplySide West.